Health
-
Johnson & Johnson to host investor conference call on second-quarter results
Jul 9, 2016News Hour: Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, July 19th, to review second-quarter results. Alex Gorsky, Chairman and Chief Executive Officer, Dominic Caruso,... -
Experts call for new strategies to address diabetes in obese patients
Jul 9, 2016News Hour: Ethicon, the medical devices subsidiary of Johnson & Johnson, is committed to leading the way in resolving the burden of obesity for both patients and healthcare systems around the world, by expanding access and... -
New janssen phase 3 data in patients with moderately to severely active rheumatoid arthritis shows sirukumab significantly inhibited radiographic progression
Jul 9, 2016News Hour: Janssen Research & Development, LLC (Janssen) announced results from a pivotal Phase 3 study evaluating subcutaneous sirukumab (CNTO 136), a human anti-interleukin (IL)-6 monoclonal antibody in development for the treatment of adults with moderately... -
New idylla™ ebola virus triage test granted emergency use authorization by u.s. fda
Jul 8, 2016News Hour: As part of Johnson & Johnson’s commitment to combat Ebola, Janssen Pharmaceutica NV announced that the Idylla™ Ebola Virus Triage Test (Idylla™ EBOV Test) was granted Emergency Use Authorization (EUA) by the U.S. Food... -
Webcast presentation on phase 3 data for darzalex® (daratumumab) and the janssen immuno-oncology strategy and portfolio
Jul 8, 2016News Hour: Janssen Research & Development, LLC and Johnson & Johnson (NYSE: JNJ) provided a pre-recorded webcast focused on Phase 3 data recently presented for DARZALEX® (daratumumab) as well as the company’s immuno-oncology strategy and portfolio. The... -
Ibrutinib (imbruvica®) granted breakthrough therapy designation by U.S. food and drug administration (FDA)
Jul 8, 2016News Hour: The U.S. Food and Drug Administration (FDA) has granted a fourth Breakthrough Therapy Designation (BTD) for ibrutinib (IMBRUVICA®): as monotherapy for the treatment of patients with chronic graft-versus-host-disease (cGVHD) after failure of one or... -
Collaborative initiative for paediatric hiv education and research (CIPHER)
Jul 8, 2016News Hour: The Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) of the International AIDS Society (IAS) is aimed at optimizing clinical management and delivery of services to infants, children and adolescents affected by HIV... -
Adolescent and youth constituency defines its contribution to the implementation of the PMNCH workplan
Jul 8, 2016News Hour: A meeting held from 4-6 July 2016, in South Africa’s Johannesburg, brought together a small group of the Partnership’s Adolescent and Youth constituency members. The aim of this meeting was to facilitate a decision... -
Anthem Blue Cross of California and VRA implement new rates for Breast Cancer patients
Jul 7, 2016News Hour: Anthem Blue Cross of California and Valley Radiotherapy Associates Medical Group (VRA) have developed a new agreement for a single episode-of-care payment for patients with a breast cancer diagnosis requiring radiation therapy treatment. The case... -
Blood test to help prevent unwarranted prescribing of antibiotics
Jul 7, 2016News Hour: An inexpensive blood test could one day tell doctors whether an infection is caused by a virus or a bacteria, and help prevent unwarranted prescribing of antibiotics, researchers said on Wednesday, reports BSS. The...